Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model

Journal of Hepatology

Volumn 48, Issue 2, 2008, Pages 308-317

  Orejuela, Diana ^a   Jorquera, Rossana ^a   Bergeron, Anne ^a   Finegold, Milton J ^b   Tanguay, Robert M ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

AKT survival pathway; Hepatocellular carcinoma; Hereditary tyrosinemia; Inhibition of intrinsic apoptosis

Indexed keywords

2 (2 NITRO 4 TRIFLUOROMETHYLBENZOYL) 1,3 CYCLOHEXADIONE; ENZYME INHIBITOR; FUMARYLACETOACETASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN KINASE B; TOXIN; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CATABOLISM; CHEMICAL ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME ACTIVATION; FEMALE; GENE INACTIVATION; HEREDITARY TYROSINEMIA TYPE 1; HISTOLOGY; IN VIVO STUDY; KNOCKOUT MOUSE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER INJURY; MITOCHONDRION; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; BCL-X PROTEIN; CARCINOMA, HEPATOCELLULAR; CYCLOHEXANONES; DISEASE MODELS, ANIMAL; HYDROLASES; LIVER NEOPLASMS; MICE; MICE, KNOCKOUT; NITROBENZOATES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TYROSINEMIAS;

EID: 38049002111     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.09.014     Document Type: Article

References (69)

1. Knox W.E., and Edwards S.W. Enzymes involved in conversion of tyrosine to acetoacetate. 5th ed. (1955), Academic Press, New York
2. Lindblad B., Lindstedt S., and Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA 74 (1977) 4641-4645
3. Kvittingen E.A., Jellum E., and Stokke O. Assay of fumarylacetoacetate fumarylhydrolase in human liver-deficient activity in a case of hereditary tyrosinemia. Clin Chim Acta 115 (1981) 311-319
4. Tanguay R.M., Valet J.P., Lescault A., Duband J.L., Laberge C., Lettre F., et al. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am J Hum Genet 47 (1990) 308-316
5. Phaneuf D., Lambert M., Laframboise R., Mitchell G., Lettre F., and Tanguay R.M. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. J Clin Invest 90 (1992) 1185-1192
6. Mitchell G.A., Grompe M., Lambert M., and Tanguay R.M. Hypertyrosinemia. 8th ed. (2001), McGraw Hill, New York
7. Tanguay R.M., Jorquera R., Poudrier J., and St-Louis M. Tyrosine and its catabolites: from disease to cancer. Acta Biochim Pol 43 (1996) 209-216
8. Jorquera R., and Tanguay R.M. The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. Biochem Biophys Res Commun 232 (1997) 42-48
9. Jorquera R., and Tanguay R.M. Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis. FASEB J 13 (1999) 2284-2298
10. Jorquera R., and Tanguay R.M. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet 10 (2001) 1741-1752
11. Endo F., Kubo S., Awata H., Kiwaki K., Katoh H., Kanegae Y., et al. Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway. J Biol Chem 272 (1997) 24426-24432
12. Kubo S., Sun M., Miyahara M., Umeyama K., Urakami K., Yamamoto T., et al. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. Proc Natl Acad Sci USA 95 (1998) 9552-9557
13. Lindstedt S., Holme E., Lock E.A., Hjalmarson O., and Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340 (1992) 813-817
14. Holme E., and Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 21 (1998) 507-517
15. Holme E., and Lindstedt S. Nontransplant treatment of tyrosinemia. Clin Liver Dis 4 (2000) 805-814
16. Luijerink M.C., Jacobs S.M., van Beurden E.A., Koornneef L.P., Klomp L.W., Berger R., et al. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). J Hepatol 39 (2003) 901-909
17. Arikan C., Kilic M., Nart D., Ozgenc F., Ozkan T., Tokat Y., et al. Hepatocellular carcinoma in children and effect of living-donor liver transplantation on outcome. Pediatr Transplant 10 (2006) 42-47
18. van Spronsen F.J., Bijleveld C.M., van Maldegem B.T., and Wijburg F.A. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro-methylbenzoyl)-1,3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr 40 (2005) 90-93
19. Buyukpamukcu M., Varan A., Haberal M., Buyukpamukcu N., Koksal Y., Coskun T., et al. The efficacy of liver transplantation in malignant liver tumors associated with tyrosinemia: clinical and laboratory findings of five cases. Pediatr Transplant 10 (2006) 517-520
20. Russo P.A., Mitchell G.A., and Tanguay R.M. Tyrosinemia: a review. Pediatr Dev Pathol 4 (2001) 212-221
21. Vogel A., van Den Berg I.E., Al-Dhalimy M., Groopman J., Ou C.N., Ryabinina O., et al. Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death. Hepatology 39 (2004) 433-443
22. Bergeron A., Jorquera R., and Tanguay R.M. Hereditary tyrosinemia: an endoplasmic reticulum stress disorder?. Med Sci (Paris) 19 (2003) 976-980
23. Coffer P.J., Jin J., and Woodgett J.R. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 335 (1998) 1-13
24. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev 13 (1999) 2905-2927
25. Rameh L.E., and Cantley L.C. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 274 (1999) 8347-8350
26. Scheid M.P., Marignani P.A., and Woodgett J.R. Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 22 (2002) 6247-6260
27. Song G., Ouyang G., and Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9 (2005) 59-71
28. Brazil D.P., Yang Z.Z., and Hemmings B.A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29 (2004) 233-242
29. Clodfelder-Miller B., De Sarno P., Zmijewska A.A., Song L., and Jope R.S. Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. J Biol Chem 280 (2005) 39723-39731
30. Luo H.R., Hattori H., Hossain M.A., Hester L., Huang Y., Lee-Kwon W., et al. Akt as a mediator of cell death. Proc Natl Acad Sci USA 100 (2003) 11712-11717
31. Nicholson K.M., and Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14 (2002) 381-395
32. Tang D., Okada H., Ruland J., Liu L., Stambolic V., Mak T.W., et al. Akt is activated in response to an apoptotic signal. J Biol Chem 276 (2001) 30461-30466
33. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., and Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30 (2004) 193-204
34. Morgensztern D., and McLeod H.L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16 (2005) 797-803
35. Testa J.R., and Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98 (2001) 10983-10985
36. Yuan Z.Q., Sun M., Feldman R.I., Wang G., Ma X., Jiang C., et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19 (2000) 2324-2330
37. Stal O., Perez-Tenorio G., Akerberg L., Olsson B., Nordenskjold B., Skoog L., et al. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5 (2003) R37-R44
38. Pesche S., Latil A., Muzeau F., Cussenot O., Fournier G., Longy M., et al. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 16 (1998) 2879-2883
39. Tanno S., Tanno S., Mitsuuchi Y., Altomare D.A., Xiao G.H., and Testa J.R. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 61 (2001) 589-593
40. Nakanishi K., Sakamoto M., Yamasaki S., Todo S., and Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 103 (2005) 307-312
41. Xu X., Sakon M., Nagano H., Hiraoka N., Yamamoto H., Hayashi N., et al. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep 11 (2004) 25-32
42. Grompe M., Lindstedt S., al-Dhalimy M., Kennaway N.G., Papaconstantinou J., Torres-Ramos C.A., et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet 10 (1995) 453-460
43. Anthony P.P., Vogel C.L., and Barker L.F. Liver cell dysplasia: a premalignant condition. J Clin Pathol 26 (1973) 217-223
44. Borzio M., Bruno S., Roncalli M., Mels G.C., Ramella G., Borzio F., et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 108 (1995) 812-817
45. Su Q., and Bannasch P. Relevance of hepatic preneoplasia for human hepatocarcinogenesis. Toxicol Pathol 31 (2003) 126-133
46. Su Q., Benner A., Hofmann W.J., Otto G., Pichlmayr R., and Bannasch P. Human hepatic preneoplasia: phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their relationship to liver cell dysplasia. Virchows Arch 431 (1997) 391-406
47. Pratt D.S., and Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 342 (2000) 1266-1271
48. Green R.M., and Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 123 (2002) 1367-1384
49. Baumann U., Preece M.A., Green A., Kelly D.A., and McKiernan P.J. Hyperinsulinism in tyrosinaemia type I. J Inherit Metab Dis 28 (2005) 131-135
50. Perry T.L. Tyrosinemia associated with hypermethioninemia and islet cell hyperplasia. Can Med Assoc J 97 (1967) 1067-1075
51. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
52. Toker A., and Newton A.C. Cellular signaling: pivoting around PDK-1. Cell 103 (2000) 185-188
53. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
54. Gross A., McDonnell J.M., and Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13 (1999) 1899-1911
55. Lizcano J.M., Morrice N., and Cohen P. Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochem J 349 (2000) 547-557
56. Virdee K., Parone P.A., and Tolkovsky A.M. Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival. Curr Biol 10 (2000) 1151-1154
57. Zha J., Harada H., Yang E., Jockel J., and Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87 (1996) 619-628
58. Datta S.R., Katsov A., Hu L., Petros A., Fesik S.W., Yaffe M.B., et al. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell 6 (2000) 41-51
59. Al-Dhalimy M., Overturf K., Finegold M., and Grompe M. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab 75 (2002) 38-45
60. Luijerink M.C., van Beurden E.A., Malingre H.E., Jacobs S.M., Grompe M., Klomp L.W., et al. Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1. Kidney Int 66 (2004) 990-1000
61. Bergeron A., Jorquera R., Orejuela D., and Tanguay R.M. Involvement of endoplasmic reticulum stress in hereditary tyrosinemia type I. J Biol Chem 281 (2006) 5329-5334
62. Leslie N.R., and Downes C.P. PTEN function: how normal cells control it and tumour cells lose it. Biochem J 382 (2004) 1-11
63. Cohen P., and Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2 (2001) 769-776
64. Pierce R.H., Vail M.E., Ralph L., Campbell J.S., and Fausto N. Bcl-2 expression inhibits liver carcinogenesis and delays the development of proliferating foci. Am J Pathol 160 (2002) 1555-1560
65. Jacobs S.M., van Beurden D.H., Klomp L.W., Berger R., and van den Berg I.E. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity. Pediatr Res 59 (2006) 365-370
66. Bosch F.X., Ribes J., and Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 19 (1999) 271-285
67. Montesano R., Hainaut P., and Wild C.P. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst 89 (1997) 1844-1851
68. Yoshiji H., Kuriyama S., Yoshii J., Yamazaki M., Kikukawa M., Tsujinoue H., et al. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 28 (1998) 1489-1496
69. Vogel A., Aslan J.E., Willenbring H., Klein C., Finegold M., Mount H., et al. Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases. Gastroenterology 130 (2006) 104-119